Zobrazeno 1 - 10
of 5 026
pro vyhledávání: '"Flinn, IW"'
Publikováno v:
Blood [Blood] 2021 Apr 01; Vol. 137 (13), pp. 1844.
Publikováno v:
Blood
The phase 2 CAVALLI (NCT02055820) study assessed efficacy and safety of venetoclax, a selective B-cell lymphoma-2 (Bcl-2) inhibitor, with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in first-line (1L) diffuse la
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8e7098fc1cf18dcf1cb5b624756a8505
https://europepmc.org/articles/PMC8020267/
https://europepmc.org/articles/PMC8020267/
Autor:
Battiwalla M; Sarah Cannon Transplant and Cellular Therapy Network, HCA Healthcare, Nashville, Tennessee, United States., Tees MT; Sarah Cannon Transplant and Cellular Therapy Network; 3. Presbyterian/St. Luke's Medical Center and Colorado Blood Cancer Institute, United States., Flinn IW; Tennessee Oncology and OneOncology, Nashville, Tennessee, United States., Pantin J; Sarah Cannon Transplant and Cellular Therapy Network, Nashville, Tennessee, United States., Berdeja JG; Tennessee Oncology, nashville, Tennessee, United States., Gregory T; Sarah Cannon Transplant and Cellular Therapy Network; Presbyterian/St. Luke's Medical Center and Colorado Blood Cancer Institute, United States., Maris MB; Sarah Cannon Transplant and Cellular Therapy Network; Presbyterian/St. Luke's Medical Center and Colorado Blood Cancer Institute, United States., Bhushan V; Sarah Cannon Blood Cancer Network, DALLAS, Texas, United States., Vance E M.D; Sarah Cannon Transplant and Cellular Therapy Network, Dallas, Texas, United States., Mathews J; Sarah Cannon Transplant and Cellular Therapy Network; Medical City Dallas Hospital and Texas Oncology, United States., Bachier C; Sarah Cannon Transplant and Cellular Therapy Network; Methodist Hospital, United States., Shaughnessy PJ; Sarah Cannon Transplant and Cellular Therapy Network; Methodist Hospital, United States., Ramakrishnan A; Sarah Cannon Transplant and Cellular Therapy Network; St. David's South Austin Medical Center, United States., Malik SA; Sarah Cannon Transplant and Cellular Therapy Network;6. St. David's South Austin Medical Center, United States., Mori S; AdventHealth Orlando, Orlando, Florida, United States., Martin C; Genospace, Inc., Kingston Springs, Tennessee, United States., Billups R; Sarah Cannon Transplant and Cellular Therapy Network, Nashville, Tennessee, United States., Blunk B; Sarah Cannon Transplant and Cellular Therapy Network, United States., LeMaistre CF; Sarah Cannon Transplant and Cellular Therapy Network, United States., Majhail NS; Tristar Centennial Medical Center, United States.
Publikováno v:
Blood advances [Blood Adv] 2024 Oct 17. Date of Electronic Publication: 2024 Oct 17.
Autor:
Danilov AV; City of Hope National Medical Center, Duarte, CA., Flinn IW; Tennessee Oncology, Nashville, TN., Davids MS; CLL Center, Dana-Farber Cancer Institute, Boston, MA., Gregory B; Secura Bio, Inc., Las Vegas, NV., Bentur O; Secura Bio, Inc., Las Vegas, NV., Sidransky D; Johns Hopkins University, Baltimore, MD., Brown JR; CLL Center, Dana-Farber Cancer Institute, Boston, MA. jennifer_brown@dfci.harvard.edu.
Publikováno v:
Haematologica [Haematologica] 2024 Oct 01; Vol. 109 (10), pp. 3379-3382. Date of Electronic Publication: 2024 Oct 01.
Autor:
Lamanna N; Herbert Irving Comprehensive Cancer Center Columbia University New York New York USA., Tam CS; Alfred Health Melbourne Victoria Australia.; Central Clinical School Monash University Melbourne Victoria Australia., Woyach JA; Division of Hematology The Ohio State University Comprehensive Cancer Center Columbus Ohio USA., Alencar AJ; Sylvester Comprehensive Cancer Center University of Miami, Miller School of Medicine Miami Florida USA., Palomba ML; Memorial Sloan Kettering Cancer Center New York New York USA., Zinzani PL; IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia 'Seràgnoli' Bologna Italy.; Dipartimento di Scienze Mediche e Chirurgiche Università di Bologna Bologna Italy., Flinn IW; Tennessee Oncology and OneOncology Nashville Tennessee USA., Fakhri B; Division of Hematology and Oncology University of California San Francisco California USA., Cohen JB; Winship Cancer Institute Emory University Atlanta Georgia USA., Kontos A; Loxo@Lilly Indianapolis Indiana USA., Konig H; Loxo@Lilly Indianapolis Indiana USA., Ruppert AS; Eli Lilly and Company Indianapolis Indiana USA., Chatterjee A; Loxo@Lilly Indianapolis Indiana USA., Sizelove R; Eli Lilly and Company Indianapolis Indiana USA., Compte L; Eli Lilly and Company Indianapolis Indiana USA., Tsai DE; Loxo@Lilly Indianapolis Indiana USA., Jurczak W; Department of Clinical Oncology Maria Sklodowska-Curie National Research Institute of Oncology Krakow Poland.
Publikováno v:
EJHaem [EJHaem] 2024 Sep 27; Vol. 5 (5), pp. 929-939. Date of Electronic Publication: 2024 Sep 27 (Print Publication: 2024).
Autor:
Maakaron J; University of Minnesota, Minneapolis, MN, United States., Asch AS; Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, United States., Popplewell L; City of Hope Medical Center, Duarte, CA, United States., Collins GP; Oxford Cancer and Haematology Centre, Churchill Hospital, Oxford, United Kingdom., Flinn IW; Sarah Cannon Research Institute at Tennessee Oncology, Nashville, TN, United States., Ghosh N; Atrium Health Levine Cancer Institute, Charlotte, NC, United States., Keane C; Princess Alexandra Hospital, Brisbane, QLD, Australia., Ku M; Department of Haematology, St. Vincent's Hospital, University of Melbourne, Melbourne, VIC, Australia., Mehta A; O'Neal Comprehensive Cancer Center at UAB, University of Alabama at Birmingham, Birmingham, AL, United States., Roschewski M; Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States., Hacohen-Kleiman G; Gilead Sciences, Inc, Foster City, CA, United States., Huo Y; Gilead Sciences, Inc, Foster City, CA, United States., Zhang Y; Gilead Sciences, Inc, Foster City, CA, United States., Renard C; Gilead Sciences, Inc, Foster City, CA, United States., Smith SM; Section of Hematology/Oncology, Department of Medicine, The University of Chicago, Chicago, IL, United States., Advani RH; Stanford Cancer Institute, Stanford University, Stanford, CA, United States.
Publikováno v:
Blood advances [Blood Adv] 2024 Sep 18. Date of Electronic Publication: 2024 Sep 18.
Autor:
Mehta A; UAB, Birmingham, Alabama, United States., Popplewell L; City of Hope, Duarte, California, United States., Collins GP; Oxford University Hospitals, Oxford, United Kingdom., Smith SM; University of Chicago, Chicago, Illinois, United States., Flinn IW; Tennessee Oncology and OneOncology, Nashville, Tennessee, United States., Bartlett NL; Washington University School of Medicine, St. Louis, Missouri, United States., Ghosh N; Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, United States., Hacohen-Kleiman G; Gilead Sciences, Inc., Foster City, California, United States., Huo Y; Gilead Sciences, Inc., Foster City, California, United States., Su-Feher L; Gilead Sciences, Inc., Foster City, California, United States., Renard C; Obsidian therapeutics, redwood city, California, United States., Advani RH; Stanford University, Stanford, California, United States., Roschewski M; National Cancer Institute, NIH, Bethesda, Maryland, United States.
Publikováno v:
Blood advances [Blood Adv] 2024 Aug 30. Date of Electronic Publication: 2024 Aug 30.
Autor:
Budde LE; City of Hope National Medical Center, Duarte, CA., Assouline S; Jewish General Hospital and McGill University, Montreal, Quebec, Canada., Sehn LH; BC Cancer Centre for Lymphoid Cancer and the University of British Columbia, Vancouver, British Columbia, Canada., Schuster SJ; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA., Yoon SS; Seoul National University Hospital, Seoul, South Korea., Yoon DH; Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea., Matasar MJ; Rutgers University, New York, NY., Bosch F; University Hospital Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain., Kim WS; Sungkyunkwan University School of Medicine, Samsung Medical Center, Seoul, South Korea., Nastoupil LJ; MD Anderson Cancer Center, Houston, TX., Flinn IW; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN., Shadman M; Fred Hutchinson Cancer Research Center, Seattle, WA., Diefenbach C; Perlmutter Cancer Center at NYU Langone Health, New York, NY., Cheah CY; Linear Clinical Research Limited, Nedlands, Australia., Ma CY; Genentech, Inc, South San Francisco, CA., Huang H; Hoffmann-La Roche Limited, Mississauga, Ontario, Canada., Kwan A; Genentech, Inc, South San Francisco, CA., Wei MC; Genentech, Inc, South San Francisco, CA., Yin S; Genentech, Inc, South San Francisco, CA., Bartlett NL; Siteman Cancer Center, Washington University School of Medicine, St Louis, MO.
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2024 Jul 01; Vol. 42 (19), pp. 2250-2256. Date of Electronic Publication: 2024 Mar 28.
Autor:
Xu L; BeiGene (Beijing) Co., Ltd., Beijing, China and BeiGene USA, Inc., San Mateo, CA. Linlin.Xu@beigene.com., Shadman M; Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA., Flinn IW; Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN., Levy MY; Texas Oncology Baylor Charles A. Sammons Cancer Center, Dallas, TX., Porter R; SSM Health Dean Medical Group, Madison, WI., Burke JM; Rocky Mountain Cancer Centers, Aurora, CO., Zafar SF; Florida Cancer Specialists and Research Institute, Fort Myers, FL., Cultrera JL; Florida Cancer Specialists and Research Institute, Leesburg, FL., Misleh J; Medical Oncology Hematology Consultants PA, Newark, DE., Kingsley EC; Comprehensive Cancer Centers of Nevada, Las Vegas, NV., Yimer HA; Texas Oncology, Tyler, TX., Freeman B; Summit Medical Group, Florham Park, NJ., Chaudhry A; Summit Cancer Centers, Spokane, WA., Tumula PK; Texas Oncology, Amarillo, TX., Gandhi MD; Virginia Cancer Specialists, Gainesville, VA., Crescenzo R; BeiGene (Beijing) Co., Ltd., Beijing, China and BeiGene USA, Inc., San Mateo, CA., By K; BeiGene (Beijing) Co., Ltd., Beijing, China and BeiGene USA, Inc., San Mateo, CA., Cohen A; BeiGene (Beijing) Co., Ltd., Beijing, China and BeiGene USA, Inc., San Mateo, CA., Chen DY; BeiGene (Beijing) Co., Ltd., Beijing, China and BeiGene USA, Inc., San Mateo, CA., Idoine A; BeiGene (Beijing) Co., Ltd., Beijing, China and BeiGene USA, Inc., San Mateo, CA., Manda S; Arizona Oncology / US Oncology Research, Tucson, AZ, USA; and., Sharman JP; Willamette Valley Cancer Institute and Research Center, Eugene, OR., Ramakrishnan V; BeiGene (Beijing) Co., Ltd., Beijing, China and BeiGene USA, Inc., San Mateo, CA.
Publikováno v:
Haematologica [Haematologica] 2024 Jul 01; Vol. 109 (7), pp. 2284-2289. Date of Electronic Publication: 2024 Jul 01.
Autor:
Munoz J; Banner MD Anderson Cancer Center, Gilbert, Arizona. Electronic address: javier.munoz@me.com., Flinn IW; Sarah Cannon Research Institute, Nashville, Tennessee., Cohen JB; Department of Hematology and Medical Oncology, Emory University, Atlanta, Georgia., Sachs J; Unum Therapeutics, Inc., Cambridge, Massachusetts., Exter B; Unum Therapeutics, Inc., Cambridge, Massachusetts., Ranger A; Unum Therapeutics, Inc., Cambridge, Massachusetts., Harris P; Unum Therapeutics, Inc., Cambridge, Massachusetts., Payumo F; Unum Therapeutics, Inc., Cambridge, Massachusetts., Nath R; Banner MD Anderson Cancer Center, Gilbert, Arizona., Hamadani M; Division of Hematology & Oncology, Medical College of Wisconsin, Milwaukee, Wisconsin., Westin JR; University of Texas M.D. Anderson Cancer Center, Houston, Texas., Bachanova V; Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, Minnesota.
Publikováno v:
Transplantation and cellular therapy [Transplant Cell Ther] 2024 Feb; Vol. 30 (2), pp. 241.e1-241.e8. Date of Electronic Publication: 2023 Oct 26.